Alert detail
LCD L39396: Allogeneic Hematopoietic Cell Transplantation for Primary Refractory or Relapsed Hodgkin's and Non-Hodgkin's Lymphoma with B-cell or T-cell Origin — Noridian
What changed
New LCD requires billing team review.
Who’s affected: Hematology billing teams · Effective: March 5, 2026
Primary source: View the official CMS/MAC document ↗
Get the action steps and full analysis
This change affects 6 billing codes.
The full analysis, the revision comparison and the as-of-date version of this policy are what a partner packet carries. The source document above is free and always will be.